This is a preview of subscription content, log in via an institution to check access.
References
Annemans L, Rémy V, Oyee J, et al. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27(3): 231–45
Merck Research Laboratories. Updated efficacy data: Gardasil®. Presentation to the American Advisory Committee on Immunization Practices (ACIP), National Immunisation Program (NIP), from the Centre for Diseases Control (CDC) (Slide show by E. Barr, MD). Feb 22, 2007
Thiry N, De Laet C, Hulstaert F, et al. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009; 25(2): 161–70
Acknowledgements
Irina Cleemput is the Senior Health Economist at the Belgian Health Care Knowledge Centre (KCE); Nancy Thiry is a Health Economist at KCE.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cleemput, I., Thiry, N. Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium. Pharmacoeconomics 27, 433 (2009). https://doi.org/10.2165/00019053-200927050-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200927050-00008